Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02547935 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 459
- Enrollment target
NCT02547935 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 459 participants.
The verdict
NCT02547935, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 459 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to determine whether dapagliflozin alone or in combination with saxagliptin can decrease albuminuria and improve glycemic control in patients with Type 2 diabetes, albuminuria and renal impairment (CKD). The study is planned to randomize a total of 450 patients (150 patients per treatment arm)
Interventions
- DRUG Dapagliflozin 10 mg
- DRUG Saxagliptin 2.5 mg
- DRUG Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 459 participants |
| Start Date | 2015-09-21 |
| Est. Completion | 2018-05-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02547935
The ClinicalTrials.gov registry entry for NCT02547935 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 459 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dapagliflozin 10 mg is the first listed.
NCT02547935 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02547935 about?
NCT02547935 is a clinical study titled "A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD". The purpose of this clinical research study is to determine whether dapagliflozin alone or in combination with saxagliptin can decrease albuminuria and improve glycemic control in patients with Type 2 diabetes, albuminuria and renal impairment (CKD). The study is planned to randomize a total of 450 ...
What is the current status of trial NCT02547935?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 459 participants. The study started on 2015-09-21. Estimated completion is 2018-05-18.
What interventions are being tested in trial NCT02547935?
The interventions under investigation include: Dapagliflozin 10 mg (DRUG), Saxagliptin 2.5 mg (DRUG), Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg (DRUG).
Who is sponsoring clinical trial NCT02547935?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.